2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. ACSL Family
  5. ACSL5 Isoform

ACSL5

Long-chain acyl-CoA synthetase ACSL5 activates long-chain fatty acids by thioesterification with CoA, generating fatty acyl-CoAs for lipid synthesis and β-oxidation[1][2]. ACSL5 localizes to the endoplasmic reticulum and mitochondrial outer membrane, where it catalyzes C16-C20 fatty acid conversion into acyl-CoA intermediates[1]. Mechanistically, ACSL5 supports fatty acid metabolism in liver, small intestine, adipose tissue, and skeletal muscle, with effects depending on substrate preference, subcellular localization, and tissue specificity[1]. In intestinal epithelium, ACSL5 is the major ACSL isoform and contributes approximately 80% of total ACSL activity, linking dietary fat absorption to enteroendocrine GLP-1 and PYY secretion[3]. In ACSL5-deficient mice, reduced adiposity, improved insulin sensitivity, increased energy expenditure, delayed triglyceride absorption, and elevated FGF21 define a metabolic model for obesity and insulin-resistance research[4]. In steatotic human liver and hepatocyte models, fatty acid uptake increases ACSL5 expression, and ACSL5 overexpression increases susceptibility to TRAIL- and TNFα-induced apoptosis through caspase activation and sphingolipid remodeling[5][6]. Compared with related ACSL isoforms, ACSL5 shows isoform-specific biology because individual ACSLs channel fatty acids into different metabolic pathways, while ACSL3 and ACSL4, but not ACSL5, support glucose-stimulated insulin secretion in β-cell models[7][8]. Current literature supports ACSL5 genetic, knockdown, overexpression, and tissue-specific ablation models, but does not establish validated ACSL5-selective agonists or inhibitors[3][4][5][6].

ACSL5 관련 제품 (6):

Cat. No. 상품명 효과 Purity
  • HY-177705
    ACSL5-IN-2
    		Inhibitor 99.51%
    ACSL5-IN-2 (Compound B) is an Acyl CoA synthetase 5 (ACSL5) inhibitor. ACSL5-IN-2 can block the conversion of long-chain fatty acids (such as palmitic acid and oleic acid) into acyl-CoA, and intervene in the fatty acid metabolism pathway. ACSL5-IN-2 can inhibit cancer cells growth. ACSL5-IN-2 can be used for the research of cancer and metabolic disease, such as colon cancer and dysfunction-associated Steatohepatitis.
  • HY-177704
    ACSL5-IN-1
    		Inhibitor 99.88%
    ACSL5-IN-1 (Compound A) is an ACSL5 inhibitor with body weight-reducing activity. ACSL5-IN-1 inhibits ACSL5, an enzyme linked to fatty acid metabolism. ACSL5-IN-1 reduces body weight in diet-induced obesity mice. ACSL5-IN-1 can be used for the research of obesity, metabolic dysfunction-associated steatohepatitis, metabolic syndrome, non-alcoholic fatty liver disease, type 2 diabetes, acute myeloid leukemia, colorectal cancer, and breast cancer.
  • HY-186095
    LP-911888
    		Inhibitor 99.83%
    LP-911888 is an orally active ACSL5/ACSL1 inhibitor, with IC50 values of 1 nM and 3 nM against mouse and human ACSL5, and IC50 values of 2 nM and 9 nM against mouse and human ACSL1, respectively. LP-911888 inhibits intestinal triglyceride uptake; it also reduces body weight and food consumption in diet-induced obese mice, and delays gastric emptying by activating the ileal brake pathway. LP-911888 can be used in studies of diet-induced obesity.
  • HY-177850
    ACSL5-IN-3
    		99.74%
    ACSL5-IN-3 (page 115 line 11) is an ACSL5 inhibitor. ACSL5-IN-3 can be used for research of tumours, digestive system diseases, and endocrine and metabolic diseases.
  • HY-186096
    LP-856866
    		Inhibitor 99.92%
    LP-856866 is an orally active ACSL5 inhibitor, with IC50 values of 8 nM and 4 nM against mouse and human ACSL5, respectively, and IC50 values of 6 nM and 17 nM against mouse and human ACSL1, respectively. LP-856866 induces delayed gastric emptying, promotes GLP-1 release, reduces food intake, decreases body weight and body fat mass, preserves lean body mass, improves glucose homeostasis, enhances insulin sensitivity, reduces hepatic lipid accumulation, and lowers serum triglyceride and total cholesterol levels. LP-856866 is applicable to research on diet-induced obesity.
  • HY-186084
    ACSL5-IN-4
    ACSL5-IN-4 (the 9th compound in Table 115) is an ACS5 inhibitor, with its IC50 value for hACS5 being less than 100 nM. ACSL5-IN-4 can be used for research in digestive and oncological diseases.